PHI with Hanot's cirrhosis
How does this condition affect your private health insurance?
Hanot-Zirrhose is an historical term for what is now known as Primary Biliary Cholangitis (PBC), and in advanced stages, Primary Biliary Cirrhosis. It's a chronic, progressive autoimmune liver disease characterized by the slow destruction of the small bile ducts within the liver. This destruction leads to cholestasis, where bile acids accumulate, causing inflammation and scarring (fibrosis), eventually progressing to cirrhosis and liver failure. Common symptoms include fatigue and pruritus (itching). Diagnosis involves liver enzyme tests, autoantibody detection (AMA), and sometimes liver biopsy. Treatment primarily involves ursodeoxycholic acid (UDCA) to slow progression.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Symptoms often develop insidiously over months to years; diagnosis can occur during asymptomatic phases, or with initial symptoms like fatigue and pruritus.
Duration of Illness (Lifetime)
Chronic and progressive, requiring lifelong management; without effective treatment, it can lead to end-stage liver disease and necessitate a liver transplant.
Cost of Treatment (Initial)
Initial diagnostic workup (blood tests, imaging, possibly biopsy) and commencement of lifelong medication can range from several thousands to tens of thousands USD, depending on the healthcare system.
Cost of Treatment (Lifetime)
High, due to lifelong medication (e.g., UDCA, obeticholic acid), regular specialist monitoring, management of complications, and potential for liver transplant, easily exceeding hundreds of thousands USD over decades.
Mortality Rate
Low in early stages with effective treatment; however, it significantly increases with advanced cirrhosis and liver failure without transplant (e.g., 10-20% within 5 years for decompensated cirrhosis if left untreated or unresponsive to therapy).
Risk of Secondary Damages
High, including severe fatigue, debilitating pruritus, osteoporosis, malabsorption, portal hypertension, ascites, variceal bleeding, hepatic encephalopathy, and ultimately, end-stage liver failure. Approximately 50-70% of patients develop significant complications over their lifetime.
Probability of Full Recovery
Extremely low. PBC is a chronic, incurable autoimmune disease. Treatment aims to halt or slow disease progression, alleviate symptoms, and prevent complications, but complete recovery without consequences is not expected.
Underlying Disease Risk
Moderate to high. PBC is frequently associated with other autoimmune conditions, such as Sjögren's syndrome (up to 70%), autoimmune thyroid disease (up to 30%), rheumatoid arthritis, scleroderma, and celiac disease.